SELLAS Life Sciences Group, Inc. Research and Development Expense
SELLAS Life Sciences Group, Inc. (SLS) reported Research and Development Expense of $15.67 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-31.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2022-03-31
- SELLAS Life Sciences Group, Inc. research and development expense for the quarter ending 2021-12-31 was $3.39M, a 22.45% increase year-over-year.
- SELLAS Life Sciences Group, Inc. research and development expense for the quarter ending 2021-09-30 was $4.54M, a 91.85% increase year-over-year.
- SELLAS Life Sciences Group, Inc. research and development expense for the quarter ending 2021-06-30 was $3.46M, a 51.58% increase year-over-year.
- SELLAS Life Sciences Group, Inc. research and development expense for the quarter ending 2021-03-31 was $4.28M, a 129.83% increase year-over-year.
- SELLAS Life Sciences Group, Inc. research and development expense for fiscal 2021 was $15.67M, a 68.86% increase from fiscal 2020.
- SELLAS Life Sciences Group, Inc. research and development expense for fiscal 2020 was $9.28M, a 27.41% increase from fiscal 2019.
- SELLAS Life Sciences Group, Inc. research and development expense for fiscal 2019 was $7.29M, a 16.90% decline from fiscal 2018.
- SELLAS Life Sciences Group, Inc. research and development expense for fiscal 2018 was $8.77M, a 44.50% increase from fiscal 2017.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed | Research and Development Expense 102 month | Research and Development Expense 105 month | Research and Development Expense 108 month | Research and Development Expense 111 month | Research and Development Expense 114 month | Research and Development Expense 120 month | Research and Development Expense 123 month | Research and Development Expense 126 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | $3.39M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $7.93M derived: sum of 2 quarters · filed 2022-03-31 | $11.39M derived: sum of 3 quarters · filed 2022-03-31 | $15.67M 10-K · filed 2022-03-31 | ||||||||||||
| 2021-09-30 | $4.54M 10-Q · filed 2021-11-12 | $8.00M derived: sum of 2 quarters · filed 2021-11-12 | $12.28M 10-Q · filed 2021-11-12 | $15.05M derived: sum of 4 quarters · filed 2022-03-31 | ||||||||||||
| 2021-06-30 | $3.46M 10-Q · filed 2021-08-12 | $7.74M 10-Q · filed 2021-08-12 | $10.51M derived: sum of 3 quarters · filed 2022-03-31 | $12.88M derived: sum of 4 quarters · filed 2022-03-31 | ||||||||||||
| 2021-03-31 | $4.28M 10-Q · filed 2021-05-13 | $7.05M derived: sum of 2 quarters · filed 2022-03-31 | $9.42M derived: sum of 3 quarters · filed 2022-03-31 | $11.70M derived: sum of 4 quarters · filed 2022-03-31 | ||||||||||||
| 2020-12-31 | $2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $5.14M derived: sum of 2 quarters · filed 2022-03-31 | $7.42M derived: sum of 3 quarters · filed 2022-03-31 | $9.28M 10-K · filed 2022-03-31 | ||||||||||||
| 2020-09-30 | $2.37M 10-Q · filed 2021-11-12 | $4.65M derived: sum of 2 quarters · filed 2021-11-12 | $6.51M 10-Q · filed 2021-11-12 | $8.76M derived: sum of 4 quarters · filed 2021-11-12 | ||||||||||||
| 2020-06-30 | $2.28M 10-Q · filed 2021-08-12 | $4.14M 10-Q · filed 2021-08-12 | $6.39M derived: sum of 3 quarters · filed 2021-08-12 | $8.19M derived: sum of 4 quarters · filed 2021-08-12 | ||||||||||||
| 2020-03-31 | $1.86M 10-Q · filed 2021-05-13 | $4.11M derived: sum of 2 quarters · filed 2021-05-13 | $5.91M derived: sum of 3 quarters · filed 2021-05-13 | $7.29M derived: sum of 4 quarters · filed 2021-05-13 | ||||||||||||
| 2019-12-31 | $2.25M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | $4.04M derived: sum of 2 quarters · filed 2021-03-23 | $5.43M derived: sum of 3 quarters · filed 2021-03-23 | $7.29M 10-K · filed 2021-03-23 | ||||||||||||
| 2019-09-30 | $1.80M 10-Q · filed 2020-11-13 | $3.18M derived: sum of 2 quarters · filed 2020-11-13 | $5.04M 10-Q · filed 2020-11-13 | $8.69M derived: sum of 4 quarters · filed 2020-11-13 | ||||||||||||
| 2019-06-30 | $1.38M 10-Q · filed 2020-08-13 | $3.24M 10-Q · filed 2020-08-13 | $6.89M derived: sum of 3 quarters · filed 2020-08-13 | $8.61M derived: sum of 4 quarters · filed 2020-08-13 | ||||||||||||
| 2019-03-31 | $1.86M 10-Q · filed 2020-05-14 | $5.51M derived: sum of 2 quarters · filed 2020-05-14 | $7.23M derived: sum of 3 quarters · filed 2020-05-14 | $8.82M derived: sum of 4 quarters · filed 2020-05-14 | ||||||||||||
| 2018-12-31 | $3.65M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $5.37M derived: sum of 2 quarters · filed 2020-03-13 | $6.96M derived: sum of 3 quarters · filed 2020-03-13 | $8.77M 10-K · filed 2020-03-13 | ||||||||||||
| 2018-09-30 | $1.72M 10-Q · filed 2019-11-14 | $3.31M derived: sum of 2 quarters · filed 2019-11-14 | $5.12M 10-Q · filed 2019-11-14 | $6.10M derived: sum of 4 quarters · filed 2019-11-14 | ||||||||||||
| 2018-06-30 | $1.59M 10-Q · filed 2019-08-14 | $3.40M 10-Q · filed 2019-08-14 | $4.38M derived: sum of 3 quarters · filed 2019-08-14 | $5.45M derived: sum of 4 quarters · filed 2019-08-14 | ||||||||||||
| 2018-03-31 | $1.80M 10-Q · filed 2019-05-15 | $2.79M derived: sum of 2 quarters · filed 2019-05-15 | $3.86M derived: sum of 3 quarters · filed 2019-05-15 | $5.69M derived: sum of 4 quarters · filed 2019-05-15 | ||||||||||||
| 2017-12-31 | $988.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | $2.06M derived: sum of 2 quarters · filed 2019-03-22 | $3.88M derived: sum of 3 quarters · filed 2019-03-22 | $6.07M 10-K · filed 2019-03-22 | ||||||||||||
| 2017-09-30 | $1.07M 10-Q · filed 2018-11-14 | $951.00K 10-Q · filed 2017-11-09 | $2.90M derived: sum of 2 quarters · filed 2018-11-14 | $5.08M 10-Q · filed 2018-11-14 | $5.36M 10-Q · filed 2017-11-09 | $1.23M derived: sum of 4 quarters · filed 2018-11-14 | ||||||||||
| 2017-06-30 | $1.83M 10-Q · filed 2018-08-14 | $2.04M 10-Q · filed 2017-08-14 | $4.01M 10-Q · filed 2018-08-14 | $4.41M 10-Q · filed 2017-08-14 | $164.00K derived: sum of 3 quarters · filed 2018-08-14 | $3.79M derived: sum of 4 quarters · filed 2018-08-14 | ||||||||||
| 2017-03-31 | $2.18M 10-Q · filed 2018-05-15 | $2.36M 10-Q · filed 2017-05-10 | -$1.66M derived: sum of 2 quarters · filed 2018-05-15 | $1.96M derived: sum of 3 quarters · filed 2018-05-15 | $8.14M derived: sum of 4 quarters · filed 2018-05-15 | |||||||||||
| 2016-12-31 | -$3.85M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-13 | -$223.00K derived: sum of 2 quarters · filed 2018-04-13 | $5.95M derived: sum of 3 quarters · filed 2018-04-13 | $11.39M 10-K · filed 2018-04-13 | ||||||||||||
| 2016-09-30 | $3.62M 10-Q · filed 2017-11-09 | $9.80M derived: sum of 2 quarters · filed 2017-11-09 | $15.24M 10-Q · filed 2017-11-09 | |||||||||||||
| 2016-06-30 | $6.17M 10-Q · filed 2017-08-14 | $11.62M 10-Q · filed 2017-08-14 | ||||||||||||||
| 2016-03-31 | $5.44M 10-Q · filed 2017-05-10 | |||||||||||||||
| 2015-09-30 | $5.74M 10-Q · filed 2016-11-09 | $12.94M derived: sum of 2 quarters · filed 2016-11-09 | $18.76M 10-Q · filed 2016-11-09 | |||||||||||||
| 2015-06-30 | $7.20M 10-Q · filed 2016-08-09 | $7.29M 10-Q · filed 2015-08-06 | $13.02M 10-Q · filed 2016-08-09 | $13.20M 10-Q · filed 2015-08-06 | ||||||||||||
| 2015-03-31 | $5.83M 10-Q · filed 2016-05-10 | $5.91M 10-Q · filed 2015-05-07 | ||||||||||||||
| 2014-09-30 | $7.03M 10-Q · filed 2015-11-09 | $7.24M 10-Q · filed 2014-11-05 | $15.09M derived: sum of 2 quarters · filed 2015-11-09 | $21.46M 10-Q · filed 2015-11-09 | $22.08M 10-Q · filed 2014-11-05 | |||||||||||
| 2014-06-30 | $8.07M 10-Q · filed 2015-08-06 | $14.84M 10-Q · filed 2015-08-06 | ||||||||||||||
| 2014-03-31 | $6.77M 10-Q · filed 2015-05-07 | |||||||||||||||
| 2013-09-30 | $3.63M 10-Q · filed 2014-11-05 | $8.91M derived: sum of 2 quarters · filed 2014-11-05 | $13.99M 10-Q · filed 2014-11-05 | $18.05M derived: sum of 4 quarters · filed 2014-11-05 | ||||||||||||
| 2013-06-30 | $5.28M 10-Q · filed 2014-08-11 | $10.36M 10-Q · filed 2014-08-11 | $14.42M derived: sum of 3 quarters · filed 2014-08-11 | $18.59M derived: sum of 4 quarters · filed 2014-08-11 | $36.15M 10-Q · filed 2013-08-09 | |||||||||||
| 2013-03-31 | $5.08M 10-Q · filed 2014-05-06 | $9.14M derived: sum of 2 quarters · filed 2014-05-06 | $13.31M derived: sum of 3 quarters · filed 2014-05-06 | $17.03M derived: sum of 4 quarters · filed 2014-05-06 | $30.87M 10-Q · filed 2013-05-09 | |||||||||||
| 2012-12-31 | $4.06M derived: 10-K 12 month − 10-Q/A 9 month · filed 2013-03-12 | $8.23M derived: sum of 2 quarters · filed 2013-11-07 | $11.95M derived: sum of 3 quarters · filed 2013-11-07 | $14.61M 10-K · filed 2013-03-12 | $25.79M 10-K · filed 2013-03-12 | |||||||||||
| 2012-09-30 | $4.17M 10-Q/A · filed 2013-11-07 | $7.89M derived: sum of 2 quarters · filed 2013-11-07 | $10.55M 10-Q/A · filed 2013-11-07 | $12.65M derived: sum of 4 quarters · filed 2013-11-07 | $21.73M 10-Q · filed 2012-11-13 | |||||||||||
| 2012-06-30 | $3.72M 10-Q · filed 2013-08-09 | $6.38M 10-Q · filed 2013-08-09 | $8.48M derived: sum of 3 quarters · filed 2013-08-09 | $9.85M derived: sum of 4 quarters · filed 2013-08-09 | $17.56M 10-Q · filed 2012-08-14 | |||||||||||
| 2012-03-31 | $2.66M 10-Q · filed 2013-05-09 | $3.67M 10-Q · filed 2012-05-14 | $4.76M derived: sum of 2 quarters · filed 2013-05-09 | $6.13M derived: sum of 3 quarters · filed 2013-05-09 | $6.45M derived: sum of 4 quarters · filed 2013-05-09 | $54.32M 10-Q · filed 2012-05-14 | ||||||||||
| 2011-12-31 | $2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-12 | $3.46M derived: sum of 2 quarters · filed 2013-03-12 | $3.79M derived: sum of 3 quarters · filed 2013-03-12 | $3.85M 10-K · filed 2013-03-12 | $11.54M 10-K · filed 2012-03-28 | $50.65M 10-K · filed 2012-03-28 | ||||||||||
| 2011-09-30 | $1.37M 10-Q · filed 2012-11-13 | $3.00M 10-Q · filed 2011-11-14 | $1.70M derived: sum of 2 quarters · filed 2012-11-13 | $1.76M 10-Q · filed 2012-11-13 | $7.83M 10-Q · filed 2011-11-14 | $5.60M derived: sum of 4 quarters · filed 2012-11-13 | $46.94M 10-Q · filed 2011-11-14 | |||||||||
| 2011-06-30 | $329.00K 10-Q · filed 2012-08-14 | $2.67M 10-Q · filed 2011-08-15 | $390.00K 10-Q · filed 2012-08-14 | $4.83M 10-Q · filed 2011-08-15 | $4.23M derived: sum of 3 quarters · filed 2012-08-14 | $6.17M derived: sum of 4 quarters · filed 2012-08-14 | $43.94M 10-Q/A · filed 2011-10-28 | |||||||||
| 2011-03-31 | $2.16M 10-Q · filed 2012-05-14 | $3.90M derived: sum of 2 quarters · filed 2012-05-14 | $5.84M derived: sum of 3 quarters · filed 2012-05-14 | $8.10M derived: sum of 4 quarters · filed 2012-05-14 | ||||||||||||
| 2010-12-31 | $1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-28 | $3.68M derived: sum of 2 quarters · filed 2012-03-28 | $5.95M derived: sum of 3 quarters · filed 2012-03-28 | $7.87M 10-K · filed 2012-03-28 | ||||||||||||
| 2010-09-30 | $1.94M 10-Q · filed 2011-11-14 | $4.20M derived: sum of 2 quarters · filed 2011-11-14 | $6.13M 10-Q · filed 2011-11-14 | |||||||||||||
| 2010-06-30 | $2.26M 10-Q/A · filed 2011-10-28 | $4.19M 10-Q/A · filed 2011-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |